Catherine Barbey

Baar, ZG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding.

Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding.

Journal: Frontiers in immunology

Published: February 09, 2026

Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials.

Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials.

Journal: Nature reviews. Rheumatology

Published: December 19, 2025

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 07, 2025

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.

Journal: Immunotherapy

Published: February 25, 2025

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.

Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.

Journal: Immunotherapy

Published: February 25, 2025

Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study.

Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study.

Journal: Lupus science & medicine

Published: December 19, 2024

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines.

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: November 29, 2024

Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?

Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?

Journal: Frontiers in medicine

Published: January 19, 2024

Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus. Reply.

Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus. Reply.

Journal: The New England journal of medicine

Published: October 19, 2022

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.

Journal: The New England journal of medicine

Published: September 07, 2022

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.

Journal: The New England journal of medicine

Published: August 08, 2022

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: January 05, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026